HRS-4508 vs Trastuzumab Deruxtecan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: HER2 · full Non-Small Cell Lung Cancer pipeline

HRS-4508

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 2 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT07003321 (registry estimate)

No aligned efficacy figure on record for this race.

Trastuzumab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in Non-Small Cell Lung Cancerantibody-drug conjugate
Weak signal

NCT03505710 · Phase 2 · terminated

Participants were placed in cohorts by HER2 status and dose without randomization, nobody was blinded to treatment, and there was no comparison arm. Response rates were read by an independent central reviewer but are reported for each cohort on its own.

Next expected readout: December 2026 · NCT06250777 (registry estimate)

Reported efficacy

Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70) (not_applicable)

Result source: NCT04644237

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHRS-4508Trastuzumab Deruxtecan
PFS, median—Not reported9.5b6.4 mg/kg · n 50NCT04644237
1 other result
  • 9.7 5.4 mg/kg · n 102 · Phase 2 · secondary NCT04644237
OS, median—Not reported17.9b6.4 mg/kg · n 50NCT04644237
1 other result
  • 19 5.4 mg/kg · n 102 · Phase 2 · secondary NCT04644237
ORR—Not reported56%b6.4 mg/kg · n 50NCT04644237
3 other results
  • 50% 5.4 mg/kg · n 102 · Phase 2 · primary NCT04644237
  • 56% 6.4 mg/kg · n 50 · Phase 2 · secondary NCT04644237
  • 46.1% 5.4 mg/kg · n 102 · Phase 2 · secondary NCT04644237
Duration of response, median—Not reported12.9b6.4 mg/kg · n 28NCT04644237
1 other result
  • 11.1 5.4 mg/kg · n 47 · Phase 2 · secondary NCT04644237

PFS, median

HRS-4508
—Not reported
Trastuzumab Deruxtecan
9.5b6.4 mg/kg · n 50NCT04644237
1 other result
  • 9.7 5.4 mg/kg · n 102 · Phase 2 · secondary NCT04644237

OS, median

HRS-4508
—Not reported
Trastuzumab Deruxtecan
17.9b6.4 mg/kg · n 50NCT04644237
1 other result
  • 19 5.4 mg/kg · n 102 · Phase 2 · secondary NCT04644237

ORR

HRS-4508
—Not reported
Trastuzumab Deruxtecan
56%b6.4 mg/kg · n 50NCT04644237
3 other results
  • 50% 5.4 mg/kg · n 102 · Phase 2 · primary NCT04644237
  • 56% 6.4 mg/kg · n 50 · Phase 2 · secondary NCT04644237
  • 46.1% 5.4 mg/kg · n 102 · Phase 2 · secondary NCT04644237

Duration of response, median

HRS-4508
—Not reported
Trastuzumab Deruxtecan
12.9b6.4 mg/kg · n 28NCT04644237
1 other result
  • 11.1 5.4 mg/kg · n 47 · Phase 2 · secondary NCT04644237
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HRS-4508: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HRS-4508: 0 of 4 rows · Trastuzumab Deruxtecan: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTrastuzumab Deruxtecan
Dropout rate
n/a: no completion milestone6.4 mg/kga
NCT04644237 · Phase 2
show 1 more result
n/a: no completion milestone5.4 mg/kg
NCT04644237 · Phase 2
Discontinued due to AEs
38%6.4 mg/kga
NCT04644237 · Phase 2
show 1 more result
17.6%5.4 mg/kg
NCT04644237 · Phase 2
Serious AEs
52%6.4 mg/kga
NCT04644237 · Phase 2
show 1 more result
41.6%5.4 mg/kg
NCT04644237 · Phase 2
Most frequent reported AEs
6.4 mg/kga
nausea 82%
decreased appetite 50%
anaemia 48%
NCT04644237 · Phase 2
show 1 more result
5.4 mg/kg
nausea 68.3%
anaemia 40.6%
decreased appetite 40.6%
NCT04644237 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Trastuzumab Deruxtecan

ORR 56% (n=50)6.4 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT04644237 · Phase 2
show 3 more results
56% (n=50)6.4 mg/kg
NCT04644237 · Phase 2
50% (n=102)5.4 mg/kg
NCT04644237 · Phase 2
46.1% (n=102)5.4 mg/kg
NCT04644237 · Phase 2
Duration of Response 12.9 months6.4 mg/kg
time to event · months
No placebo or comparator arm
NCT04644237 · Phase 2
show 1 more result
11.1 months5.4 mg/kg
NCT04644237 · Phase 2
Disease Control 88% (n=50)6.4 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT04644237 · Phase 2
show 1 more result
90.2% (n=102)5.4 mg/kg
NCT04644237 · Phase 2
PFS 9.5 months6.4 mg/kg
time to event · months
No placebo or comparator arm
NCT04644237 · Phase 2
show 1 more result
9.7 months5.4 mg/kg
NCT04644237 · Phase 2
Overall Survival 17.9 months6.4 mg/kg
time to event · months
No placebo or comparator arm
NCT04644237 · Phase 2
show 1 more result
19 months5.4 mg/kg
NCT04644237 · Phase 2
EORTC QLQ-C30 15.63 score6.4 mg/kg
absolute change · score
No placebo or comparator arm
QLQ-C30: Change from Baseline 40-Day Follow-up
NCT04644237 · Phase 2
show 1 more result
-1.11 score5.4 mg/kg
QLQ-C30: Change from Baseline 40-Day Follow-up
NCT04644237 · Phase 2
EORTC QLQ-LC13 -29.17 score6.4 mg/kg
absolute change · score
No placebo or comparator arm
QLQ-LC13: Change from Baseline 40-Day Follow-up
NCT04644237 · Phase 2
show 1 more result
-2.38 score5.4 mg/kg
QLQ-LC13: Change from Baseline 40-Day Follow-up
NCT04644237 · Phase 2
Time to Deterioration QLQ-C30 9.3 months6.4 mg/kg
time to event · months
No placebo or comparator arm
NCT04644237 · Phase 2
show 1 more result
8.6 months5.4 mg/kg
NCT04644237 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-4508's landscape · Trastuzumab Deruxtecan's landscape